Biophotonics and Biotechnology in Pancreatic Cancer: Cyclic RGD-Peptide-Conjugated Type II Quantum Dots for in vivo Imaging

Yong, Ken‐Tye

doi:10.1159/000283577

Cited by 24 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[35][36][37][38] In addition, tissue sections, biodistribution, and pharmacokinetics of cRGD-peptide-conjugated quantum dots (QDs), 39 gold nanoclusters, 40 doxorubicin-loaded nanoparticles, 41 polymeric micelles, 42 and dendrimers 43 were imaged or analyzed in mice bearing tumor xenografts, confirming specific tumor targeting. All the results presented here as well as reports in the literature suggest that cRGD-Lipo-PEG liposomes would result in improved tumor inhibition in mouse models.…”

mentioning

confidence: 96%

Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

Song

Lin

Zhang

et al. 2017

IJN

View full text Add to dashboard Cite

Apatinib is an oral tyrosine kinase inhibitor, which selectively targets vascular endothelial growth factor receptor 2 and has the potential to treat many tumors therapeutically. Cyclic arginylglycylaspartic acid (cRGD)- and polyethylene glycol (PEG)-modified liposomes (cRGD-Lipo-PEG) were constructed to act as a targeted delivery system for the delivery of apatinib to the human colonic cancer cell line, HCT116. These cRGD-modified liposomes specifically recognized integrin α v β 3 and exhibited greater uptake efficiency with respect to delivering liposomes into HCT116 cells when compared to nontargeted liposomes (Lipo-PEG), as well as greater death of tumor cells and apoptosis. The mechanism by which cRGD-Lipo-PEG targets cells was elucidated further with competition assays. To determine the anticancer efficacy in vivo, nude mice were implanted with HCT116 xenografts and treated with apatinib-loaded liposomes or free apatinib intravenously or via intragastric administration. The active and passive targeting of cRGD-Lipo-PEG led to significant tumor treatment targeting ability, better inhibition of tumor growth, and less toxicity when compared with treatments using uncombined apatinib. The results presented strongly support the case for cRGD-Lipo-PEG representing a targeted delivery system for apatinib in the treatment of colonic cancer.

show abstract

mentioning

confidence: 96%

Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

Song

Lin

Zhang

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…QDs are special semiconductor nanocrystals with sizes ranging from 2 to 10 nm that contain hundreds to thousands of atoms of group II-VI or III-V elements [18]. Compared with traditional organic fluorescent dyes, the use of QDs as fluorescent biological probes has the following advantages.…”

Section: Discussionmentioning

confidence: 99%

Peptide-Conjugated Quantum Dots Act as the Target Marker for Human Pancreatic Carcinoma Cells

Li¹,

Yang²,

Lei³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: In the present study, we describe a novel and straightforward approach to produce a cyclic- arginine-glycine-aspartic (RGD)-peptide-conjugated quantum dot (QD) probe as an ideal target tumor biomarker. Due to its specific structure, the probe can be used for targeted imaging of pancreatic carcinoma cells. Methods: Pancreatic carcinoma cells were routinely cultured and marked with QD-RGD probe. The QD-RGD probe on the fluorescence-labeled cancer cell was observed by fluorescence microscopy and laser confocal microscopy. Cancer cell viability was detected by MTT assay after culturing with QD-RGD probe. Results: Fluorescence microscopy and laser confocal microscopy displayed that 10nmol/L QD-RGD probe was able to effectively mark pancreatic carcinoma cells. In comparison with organic dyes and fluorescent proteins, the quantum dot-RGD probe had unique optical and electronic properties. Conclusion: QD-RGD probe has a low cytotoxicity with an excellent optical property and biocompatibility. These findings support further evaluation of QD-RGD probes for the early detection of pancreatic cancer.

show abstract

“…These functional QD probes have been increasingly used in cellular and molecular tracing, in vivo tumor imaging, drug monitoring and signal transduction [32,33]. Functionalized QDs for in vivo imaging of the vasculature in pancreatic tumors can significantly improve early diagnosis [34,35]. Cyclic arginine-glycine-aspartic acid (cRGD) peptide conjugated to CdTe/CdS QDs are ultrasensitive NPs for detection of pancreatic tumor vasculature by optical future science group Nanoformulations for therapy of pancreatic & liver cancers Review imaging [34,35].…”

Section: Quantum Dotsmentioning

confidence: 99%

“…Functionalized QDs for in vivo imaging of the vasculature in pancreatic tumors can significantly improve early diagnosis [34,35]. Cyclic arginine-glycine-aspartic acid (cRGD) peptide conjugated to CdTe/CdS QDs are ultrasensitive NPs for detection of pancreatic tumor vasculature by optical future science group Nanoformulations for therapy of pancreatic & liver cancers Review imaging [34,35]. To address the issues of QD toxicity, poor stability and low targeting efficiency [36], carboxylated PluronicF127 modified QDs conjugated to an antimesothelin antibody (Me-F127COOH-QD), for efficient tumor targeting, have also been proposed.…”

Section: Quantum Dotsmentioning

confidence: 99%

Nanoformulations for Therapy of Pancreatic and Liver Cancers

Souza

Ranjan

Towner

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Pancreatic and liver cancers often have poor prognoses. Clinically, pancreatic and liver cancer requires early diagnosis, and surgery is often associated with tumor recurrence. Currently, chemotherapies are limited in their ability to accurately target the tumors, and are associated with significant toxicity in patients. Targeting of chemotherapy can be improved by encapsulation in nanocarriers. A variety of preclinical studies indicate relatively superior therapeutic outcomes compared with drug alone therapy. Targeted nanoparticle imaging agents may also additionally facilitate better diagnosis and improve patient outcomes. This review discusses the nanoformulations that are under investigation (mainly preclinical studies, but also with some current clinical trial examples) against pancreatic and liver cancers, understands the challenges and provides future perspectives.

show abstract

Biophotonics and Biotechnology in Pancreatic Cancer: Cyclic RGD-Peptide-Conjugated Type II Quantum Dots for in vivo Imaging

Cited by 24 publications

References 44 publications

Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

Peptide-Conjugated Quantum Dots Act as the Target Marker for Human Pancreatic Carcinoma Cells

Nanoformulations for Therapy of Pancreatic and Liver Cancers

Contact Info

Product

Resources

About